



## **Press release**

### **NeurogesX Launches IPO on NASDAQ**

**Munich/Zug, May 11, 2007** – Global Life Science Ventures (GLSV) is pleased to announce that its portfolio company NeurogesX has launched an IPO on the NASDAQ Global Market, trading since May 2, 2007 under the symbol “NGSX”.

NeurogesX offered 4,000,000 shares of common stock at \$11.00 per share, with an additional over-allotment option to the underwriters to purchase up to 600,000 additional shares. Morgan Stanley acted as the sole book running and lead manager for the offering, while Pacific Growth Equities, LLC, Lazard Capital Markets LLC and Susquehanna Financial Group, LLLP acted as co-managers.

NeurogesX is a biopharmaceutical company focused on the development of effective treatments to relieve chronic pain. Its most advanced product candidate, NGX-4010, is a cutaneous patch designed to treat peripheral neuropathic pain conditions. The compound has already successfully completed two Phase III clinical trials, and the Company is currently in the process of registering it in Europe.

Dr. Holger Reithinger, Partner at GLSV, commented, “We are happy that NeurogesX was able to raise \$44 million in a difficult market environment. These proceeds will enable the company to complete additional running pivotal phase III studies and to support the European Marketing Authorization Approval process. This will constitute further positive news flow in the upcoming months, supporting the development of the company.”

Dr. Peter Reinisch, Partner at GLSV, added, "We have supported NeurogesX as co-lead investor since February 2004 and seen the company overcome a difficult period with its first pivotal trial. As the company's biggest European investor, we are pleased that NGX-4010 will potentially be registered soon in Europe."

#### **About Global Life Science Ventures:**

GLSV is a leading, independent venture capital fund focusing exclusively on the life sciences. With offices in Germany and Switzerland, GLSV is dedicated to supporting early-stage companies originating from universities, scientific institutions or industry, but also invests in selected later-stage companies, including buy-outs. The group currently advises and manages funds totalling more than €200 million. GLSV has now financed 32 innovative life science companies, 13 of which have completed an exit through IPO, trade sale or M&A. GLSV has built up a broadly diversified portfolio of companies in pharmaceuticals, diagnostics, medical devices, and biotechnology.

## **Global Life Science Ventures**

**Industry-born team – Proven track record – Global perspective**

### **Germany**

GLSV GmbH  
Von-der-Tann-Str. 3  
D – 80539 München  
Tel. +49 (0)89 288 151 0  
Fax +49 (0)89 288 151 30  
[www.glsv-vc.com](http://www.glsv-vc.com)  
[mailbox@glsv-vc.com](mailto:mailbox@glsv-vc.com)

### **Switzerland**

GLSV AG  
Postplatz 1, P.O. 626  
CH – 6301 Zug  
Tel. +41 (0)41 727 19 40  
Fax +41 (0)41 727 19 45

For additional information, please contact:

### **Rochat & Partners**

Christophe Lamps or Jonathan Leighton  
Tel. +41 22 718 37 46  
Fax +41 22 786 54 58  
E-mail: [clamps@rochat-pr.ch](mailto:clamps@rochat-pr.ch)  
[jleighton@rochat-pr.ch](mailto:jleighton@rochat-pr.ch)

### **MC Services (Germany)**

Raimund Gabriel  
Tel. +49 (0) 89 210 228 30  
Fax +49 (0) 89 210 228 88  
E-mail: [gabriel@mc-services.de](mailto:gabriel@mc-services.de)